Trial Profile
A Phase II Trial of Gemcitabine and Oxaliplatin for ER-, PR-, HER2NEU- (Triple Negative) Metastatic Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary) ; Gemcitabine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 21 Dec 2011 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 21 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jun 2011 Planned end date changed from May 2010 to Nov 2011 as reported by ClinicalTrials.gov.